MiCareo is a venture capital-backed start-up based in the Neihu Technology Park in the Taiwanese capital city Taipei, where it occupies over 1,400 square meters of laboratory and office space, including a certified microfluidic chip manufacturing space (ISO class 4 in accordance with DIN EN ISO 14644-1). Its state-of-the-art facilities have attracted an impressive team of experts in microfluidics, optics, engineering, software, biology, clinical practice and regulatory approval. MiCareo believes the future lies in precision medicine - offering the right treatment for the right patient at the right time. In pursuit of this goal, MiCareo is intently focused on unlocking the crucial information hidden away deep inside the cells that circulate around our bodies.
The result of this ambitious endeavor is the MiSelect R System, which the company is now unveiling at LABVOLUTION 2019 in Hannover. MiCareo explains that from just one tube of blood, this device can isolate and profile a single live cell to extract biological and genomic information. The system is capable of characterizing up to 13 biomarkers for analysis with integrated staining and imaging, and also makes it possible to retrieve single cells for downstream analysis. The team will be delighted to explain more about the functions and provide further details at LABVOLUTION in Hannover.